Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics | ||
By: PR Newswire Association LLC. - 16 Feb 2024 | Back to overview list |
|
- Innovative universal, off-the-shelf in vivo CAR-T Cell therapy - TOKYO and BOSTON, Feb. 15, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Kelonia Therapeutics (CEO, Founder: Kevin Friedman, Ph.D., "Kelonia") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics. Kelonia is a biotech company pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS®). iGPS® uses next generation lentiviral particles to efficiently deliver genetic cargo precisely to the desired target cells inside the patient's body. Xyphos holds a novel and proprietary ACCEL™ technology*1 platform that uses its convertibleCAR® (convertible Chimeric Antigen Receptor)*1 on immune cells. Under the terms of the agreement, the companies plan to combine Kelonia's iGPS® with Xyphos' ACCEL™ technology to develop innovative in vivo CAR-T Cell therapies*2 targeting up to two programs. Xyphos will be responsible for the development and commercialization of products created from the collaborative research. Kelonia will receive US $40 million upfront for the first program, and an additional US $35 million should Xyphos exercise its options for the second program, and potential milestones and contingency payments approaching US $800 million in total. Additionally, Kelonia will receive R&D funding for work performed in the collaboration and is eligible for tiered royalties on net sales up to the double digit percentage. Kevin Friedman, Ph.D., CEO and Founder of Kelonia Adam Pearson, Chief Strategy Officer (CStO) of Astellas About Astellas About Xyphos Biosciences, Inc., an Astellas Company About Kelonia Therapeutics Cautionary Notes (Astellas) Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. *1 ACCEL™ technology and convertibleCAR®: ACCEL™ technology is based on a synthetic biology approach that utilizes the binding of an engineered protein ligand to an orthogonal engineered receptor which forms the extracellular domain of a convertible CAR (chimeric antigen receptor). The convertibleCAR® is targeted to tumor cells with a tumor-associated antigen-specific engineered antibody-like molecule (MicAbody) containing the engineered ligand. For more information, please visit http://www.xyphosinc.com *2 in vivo CAR-T cell therapies: A therapy in which the CAR gene is introduced into the patient's cells residing in the body. The CAR gene is expressed in vivo to create immune cells that identify and attack cancer cells. Unlike conventional CAR-T cell therapy, there is no need to culture the extracted immune cells outside the body and then return them to the patient after conditioning chemotherapy, which is expected to be more tolerable and accelerate treatment to improve patients' access to the therapy.S *3: Astellas has established a Focus Area Approach for its research and development strategy. For more information, please visit our website at Areas of Interest | Astellas Pharma Inc. View original content to download multimedia:https://www.prnewswire.com/news-releases/astellas-and-kelonia-therapeutics-enter-into-research-and-license-agreement-to-develop-novel-immuno-oncology-therapeutics-302063599.html SOURCE ASTELLAS PHARMA INC. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |